近視性網脈絡膜萎縮を対象に開発中の再生医療等製品「PAL-222」に関する ファーマバイオ株式会社との国内独占販売契約締結のお知らせ [PDF:161KB]

Rohto Pharmaceutical Co. Ltd. published this content on September 30, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 30, 2026 at 06:34 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]